MDM2

MDM2
Strwythurau
PDB	Human UniProt search: PDBe RCSB
Rhestr o ddynodwyr PDB
	1RV1, 1T4E, 1T4F, 1YCR, 1Z1M, 2AXI, 2C6A, 2C6B, 2FOP, 2GV2, 2HDP, 2LZG, 2M86, 2MPS, 2RUH, 2VJE, 2VJF, 3EQS, 3G03, 3IUX, 3IWY, 3JZK, 3JZR, 3JZS, 3LBK, 3LBL, 3LNJ, 3LNZ, 3MQS, 3TJ2, 3TPX, 3TU1, 3V3B, 3VBG, 3VZV, 3W69, 4DIJ, 4ERE, 4ERF, 4HBM, 4HFZ, 4HG7, 4JV7, 4JV9, 4JVE, 4JVR, 4JWR, 4MDN, 4MDQ, 4OAS, 4OBA, 4OCC, 4ODE, 4ODF, 4OGN, 4OGT, 4OGV, 4OQ3, 4QO4, 4QOC, 4UMN, 4WT2, 4XXB, 4ZYC, 4ZYF, 4ZYI, 4UE1, 4UD7, 5AFG, 5HMI, 5HMK, 5HMH, 5C5A
Dynodwyr
Cyfenwau	MDM2, ACTFS, HDMX, hdm2, MDM2 proto-oncogene, LSKB
Dynodwyr allanol	OMIM: 164785 HomoloGene: 1793 GeneCards: MDM2
Patrwm RNA pattern
	; ; ; ;
	Rhagor o gyfeiriadau
Ontoleg y genyn
Gweithrediad moleciwlaidd	• scaffold protein binding; • GO:0001948, GO:0016582 protein binding; • enzyme binding; • metal ion binding; • identical protein binding; • ubiquitin protein ligase binding; • p53 binding; • SUMO transferase activity; • GO:0050372 ubiquitin-protein transferase activity; • transferase activity; • ligase activity; • 5S rRNA binding; • zinc ion binding; • ribonucleoprotein complex binding; • protein N-terminus binding; • GO:1904264, GO:1904822, GO:0090622, GO:0090302 ubiquitin protein ligase activity; • NEDD8 ligase activity; • disordered domain specific binding; • protein domain specific binding; • receptor serine/threonine kinase binding; • peroxisome proliferator activated receptor binding; • ubiquitin binding;
Cydrannau o'r gell	• cytosol; • endocytic vesicle membrane; • Cellbilen; • synapse; • nuclear body; • cytoplasm; • cnewyllyn cell; • nucleoplasm; • nucleolus; • GO:0009327 protein-containing complex;
Prosesau biolegol	• negative regulation of signal transduction by p53 class mediator; • endocardial cushion morphogenesis; • cellular response to UV-C; • atrial septum development; • regulation of heart rate; • DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest; • GO:1901313 positive regulation of gene expression; • blood vessel development; • positive regulation of cell population proliferation; • negative regulation of DNA damage response, signal transduction by p53 class mediator; • response to ether; • blood vessel remodeling; • cellular response to hypoxia; • heart valve development; • cellular response to estrogen stimulus; • negative regulation of apoptotic process; • cellular response to organic substance; • cellular response to hydrogen peroxide; • adwaith i gocên; • cardiac septum morphogenesis; • GO:1901227 negative regulation of transcription by RNA polymerase II; • GO:0018054 peptidyl-lysine modification; • positive regulation of cell cycle; • ventricular septum development; • positive regulation of protein export from nucleus; • response to steroid hormone; • cellular response to growth factor stimulus; • GO:1903362 regulation of protein catabolic process; • GO:1904577 cellular response to antibiotic; • negative regulation of gene expression; • positive regulation of mitotic cell cycle; • heart development; • cellular response to alkaloid; • cellular response to vitamin B1; • response to magnesium ion; • negative regulation of cysteine-type endopeptidase activity involved in apoptotic process; • positive regulation of proteasomal ubiquitin-dependent protein catabolic process; • cellular response to peptide hormone stimulus; • GO:1904579 cellular response to organic cyclic compound; • GO:0022415 viral process; • response to iron ion; • regulation of gene expression; • GO:1904576 response to antibiotic; • traversing start control point of mitotic cell cycle; • protein ubiquitination; • negative regulation of protein processing; • establishment of protein localization; • response to toxic substance; • response to morphine; • atrioventricular valve morphogenesis; • protein localization to nucleus; • regulation of signal transduction by p53 class mediator; • positive regulation of vascular associated smooth muscle cell proliferation; • response to water-immersion restraint stress; • negative regulation of neuron projection development; • positive regulation of vascular associated smooth muscle cell migration; • protein deubiquitination; • protein sumoylation; • transcription factor catabolic process; • protein autoubiquitination; • response to formaldehyde; • protein destabilization; • GO:0045996 negative regulation of transcription, DNA-templated; • proteolysis involved in cellular protein catabolic process; • cellular response to gamma radiation; • cellular response to actinomycin D; • negative regulation of intrinsic apoptotic signaling pathway by p53 class mediator; • amyloid fibril formation; • GO:0034622 protein-containing complex assembly; • ubiquitin-dependent protein catabolic process;
	Sources:Amigo / QuickGO
Orthologau
	4193
	n/a
	ENSG00000135679
	n/a
	Q00987
	n/a
NM_001145336; NM_001145337; NM_001145339; NM_001145340; NM_001278462;
	NM_002392; NM_006878; NM_006879; NM_006880; NM_006881; NM_006882; NM_032739; NM_001367990
	n/a
NP_001138809; NP_001138811; NP_001138812; NP_001265391; NP_002383;
	NP_001354919
	n/a
	Wicidata
Gweld/Golygu Bod dynol

Protein sy'n cael ei godio yn y corff dynol gan y genyn MDM2 yw MDM2 a elwir hefyd yn E3 ubiquitin-protein ligase Mdm2 (Saesneg). Segment o DNA yw'r genyn, sy'n amgodio ffwythiant arbennig. Mae'r genyn yma wedi ei leoli ar yr edefyn blaen o gromosom dynol 12, band 12q15.^[2]

Cyfystyron[golygu | golygu cod]

Yn aml mae gan enynnau lawer o gyfystyron. Mae hyn oherwydd eu bod yn aml yn cael eu darganfod gan nifer o bobl mewn cyd-destunau gwahanol heb wybod mai'r un genynnau oeddyn nhw. Hefyd mae gan wahanol gymunedau gwyddonol safonau gwahanol ar gyfer enwi genynnau. Dyma restr o gyfystyron ar gyfer y genyn MDM2.

HDMX
hdm2
ACTFS

Llyfryddiaeth[golygu | golygu cod]

"Inactivation of the MDM2 RING domain enhances p53 transcriptional activity in mice. ". J Biol Chem. 2017. PMID 29123033.
"Introduction of the MDM2 T309G Mutation in Primary Human Retinal Epithelial Cells Enhances Experimental Proliferative Vitreoretinopathy. ". Invest Ophthalmol Vis Sci. 2017. PMID 29049737.
"MDM2 promotes epithelial-mesenchymal transition and metastasis of ovarian cancer SKOV3 cells. ". Br J Cancer. 2017. PMID 28817834.
"Association of MDM2 expression with shorter progression-free survival and overall survival in patients with advanced pancreatic cancer treated with gemcitabine-based chemotherapy. ". PLoS One. 2017. PMID 28678832.
"HIV-1 Tat potently stabilises Mdm2 and enhances viral replication.". Biochem J. 2017. PMID 28468838.

Cyfeiriadau[golygu | golygu cod]

[1] "Human PubMed Reference:".

[2] MDM2 - Cronfa NCBI

[1]

[2]